Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 45Unknown 7Terminated 6Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 27INDUSTRY 6NETWORK 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 38Lymphoma 38Lung Neoplasms 25Ovarian Neoplasms 24Melanoma 23Neoplasm Metastasis 21Hematologic Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 19Fallopian Tube Neoplasms 19Breast Neoplasms 18Prostatic Neoplasms 17Glioma 17Sarcoma 14Carcinoma, Renal Cell 14Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Lymphoma, Non-Hodgkin 12Urinary Bladder Neoplasms 11Small Cell Lung Carcinoma 11Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 11Glioblastoma 11Triple Negative Breast Neoplasms 10Pancreatic Neoplasms 10Medulloblastoma 10Wilms Tumor 9Sarcoma, Ewing 9Rhabdomyosarcoma 9Rhabdoid Tumor 9

Interventions

Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NIH × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT00070499 2026-05-29

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
406 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡